RSLS - ReShape Lifesciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5751.75k
Enterprise Value 31.7M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)0.21
Price/Book (mrq)0.02
Enterprise Value/Revenue 30.48
Enterprise Value/EBITDA 6-0.09

Trading Information

Stock Price History

Beta (3Y Monthly) 2.47
52-Week Change 3-99.21%
S&P500 52-Week Change 32.16%
52 Week High 311.2000
52 Week Low 30.0400
50-Day Moving Average 30.0812
200-Day Moving Average 30.1663

Share Statistics

Avg Vol (3 month) 3176.92k
Avg Vol (10 day) 356.08k
Shares Outstanding 511.06M
Float 11.06M
% Held by Insiders 10.01%
% Held by Institutions 17.49%
Shares Short (Dec 14, 2018) 4132.12k
Short Ratio (Dec 14, 2018) 40.06
Short % of Float (Dec 14, 2018) 433.68%
Short % of Shares Outstanding (Dec 14, 2018) 41.73%
Shares Short (prior month Nov 15, 2018) 4168.59k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2140/1
Last Split Date 3Nov 8, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)-559.99%

Management Effectiveness

Return on Assets (ttm)-19.68%
Return on Equity (ttm)-68.54%

Income Statement

Revenue (ttm)3.54M
Revenue Per Share (ttm)1.12
Quarterly Revenue Growth (yoy)2,111.50%
Gross Profit (ttm)442.41k
EBITDA -19.07M
Net Income Avi to Common (ttm)-35.45M
Diluted EPS (ttm)-24.3980
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.83M
Total Cash Per Share (mrq)0.17
Total Debt (mrq)2.58M
Total Debt/Equity (mrq)9.02
Current Ratio (mrq)0.78
Book Value Per Share (mrq)3.71

Cash Flow Statement

Operating Cash Flow (ttm)-23.87M
Levered Free Cash Flow (ttm)-9.88M